Affectis Pharmaceuticals AG Announces Target Validation Collaboration with Mitsubishi Pharma

08-Feb-2005

Affectis Pharmaceuticals AG announced that it has signed a collaboration agreement with Mitsubishi Pharma Corporation for the development of novel therapeutics for the treatment of affective disorders. Under the terms of the agreement, Affectis will apply its pioneering target validation technology and its exclusive animal models for the validation of Mitsubishi Pharma's gene targets involved in depression and anxiety.

Today, one of the major challenges in developing optimised drugs against affective disorders is the limited availability of suitable animal models and sufficient expertise in selecting promising targets and leads as well as their preclinical development. Affectis´ team has experience in developing, performing and interpreting behavioural assays and animal models of diseases such as depression and anxiety.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances